Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

NCT02012296 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02012296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Lead sponsor
University of Chicago
Phase
Phase 1/2
Overall status
Completed
Start date
December 13, 2013
Completion date
August 1, 2020
Enrollment
88 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer